Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379080 · ClinicalTrials.gov registry record · Phase 1
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00379080: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00379080 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00379080, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Interventions
- OTHER pharmacological study
- PROCEDURE conventional surgery
- DRUG tandutinib
- OTHER Tissue samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00379080
The ClinicalTrials.gov registry entry for NCT00379080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pharmacological study is the first listed.
NCT00379080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00379080 about?
NCT00379080 is a clinical study titled "Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma". This phase I/II trial is studying the side effects and best dose of tandutinib and to see how well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow ...
What is the current status of trial NCT00379080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2007-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00379080?
The interventions under investigation include: pharmacological study (OTHER), conventional surgery (PROCEDURE), tandutinib (DRUG), Tissue samples (OTHER).
Who is sponsoring clinical trial NCT00379080?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.